Shortening development and review timelines, thinking more like a regulator



EUAs during COVID – **600**

EUAs amidst other public health emergencies – **65**

Increased collaboration between regulatory agencies and industry enabled shorter review timelines for COVID-19 drugs and treatments

Regulators around the world worked hand-in-hand with industry rather than just having an endpoint type of review, and it is anticipated that these run-on trials will be the case post-COVID

The future of regulatory is **digital** and **collaborative**

"Think like a regulator"

- Patient safety first
- Risk based approach
- Objective evidence
- A controlled process

Learn more at www.deloitte.com/lifesciencesoutlook